Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...

A biotech-focused venture capital firm in Chicago is ready with a new fund as life sciences and biotech continue to find new ...

ARCH Venture Partners is the latest venture capital firm to raise a multi-billion-dollar fund. The cash will be used to ...

On the heels of a $3 billion fund from Bain Capital Life Sciences, Arch Venture Partners is proving it can go toe-to-toe with ...

Today, a brief rundown of news from Biogen, as well as updates from Dyne Therapeutics, Denali Therapeutics and Novo Nordisk that you may have missed.

An experimental weight loss pill developed by biotechnology company Terns Pharmaceuticals helped some people with obesity lose more than 5% of their body weight in a small Phase 1 trial, supporting ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

In collaboration with partner HHP, University of Chicago Medicine's food hall at the Center for Care and Discovery (CCD) is celebrating its grand opening this ...

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 ...

Bio-Techne Corporation today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...